Compare PRZO & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRZO | NCEL |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | Israel | Switzerland |
| Employees | N/A | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 17.2M |
| IPO Year | 2022 | N/A |
| Metric | PRZO | NCEL |
|---|---|---|
| Price | $0.53 | $3.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.8M | 30.7K |
| Earning Date | 03-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $1.83 |
| 52 Week High | $2.15 | $5.12 |
| Indicator | PRZO | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.44 | 58.05 |
| Support Level | $0.45 | $2.95 |
| Resistance Level | $0.82 | $3.62 |
| Average True Range (ATR) | 0.06 | 0.26 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 4.48 | 90.56 |
ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.